Changeflow GovPing Healthcare & Life Sciences Apotex Multiple Vitamins Injection Pediatric Ap...
Routine Rule Added Final

Apotex Multiple Vitamins Injection Pediatric Approved 04/21/2026

Favicon for www.accessdata.fda.gov FDA Drugs@FDA - New Applications and Actions
Published
Detected
Email

Summary

The FDA granted Apotex approval for ANDA 210671 covering Multiple Vitamins Injection Pediatric, an injectable multivitamin formulation for pediatric patients administered intravenously. The product contains 13 active ingredients including ascorbic acid, B-complex vitamins, and fat-soluble vitamins A, D, E, and K. Apotex's approved formulation is therapeutically equivalent (TE Code: AP) to Sandoz Canada's reference listed drug Infuvite Pediatric, enabling Apotex to market the generic as a prescription injectable product.

Published by FDA on accessdata.fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Drugs@FDA - New Applications and Actions for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 14 changes logged to date.

What changed

The FDA approved Apotex's Abbreviated New Drug Application (ANDA 210671) for Multiple Vitamins Injection Pediatric, an injectable prescription multivitamin product for pediatric patients administered intravenously. The product carries TE Code AP, establishing therapeutic equivalence to Sandoz Canada's approved reference listed drug Infuvite Pediatric. Apotex becomes the second approved supplier of this specific pediatric injectable multivitamin formulation, alongside Sandoz Canada and a related Apotex pharmacy bulk package product.

Pharmaceutical manufacturers and healthcare providers should note this additional market entry for pediatric injectable multivitamins. Hospitals and infusion centers sourcing these products may now have an additional approved supplier for formulary consideration.

Archived snapshot

Apr 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

*Home | *

Abbreviated New Drug Application (ANDA): 210671
Company: APOTEX
- Email

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
MULTIPLE VITAMINS INJECTION PEDIATRIC ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL INJECTABLE;INTRAVENOUS Prescription AP No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
04/21/2026 ORIG-1 Approval STANDARD Label is not available on this site.

MULTIPLE VITAMINS INJECTION PEDIATRIC

INJECTABLE;INTRAVENOUS; 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL
TE Code = AP

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
INFUVITE PEDIATRIC ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL INJECTABLE;INTRAVENOUS Prescription Yes AP 021265 SANDOZ CANADA INC
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE) ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL INJECTABLE;INTRAVENOUS Prescription Yes AP 021265 SANDOZ CANADA INC
MULTIPLE VITAMINS INJECTION PEDIATRIC ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL INJECTABLE;INTRAVENOUS Prescription No AP 210671 APOTEX
MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL INJECTABLE;INTRAVENOUS Prescription No AP 210456 APOTEX

Get daily alerts for FDA Drugs@FDA - New Applications and Actions

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Generic drug approval Prescription drug marketing Injectable pharmaceuticals
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Compliance frameworks
GxP
Topics
Medical Devices Healthcare

Get alerts for this source

We'll email you when FDA Drugs@FDA - New Applications and Actions publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!